Genascence to Present Full Data from Phase 1 Clinical Trial on GNSC-001, Company’s Lead Program in Osteoarthritis, at European Society of Gene & Cell Therapy 30th Annual Congress

By / 24/10/2023

Genascence Corporation announced that data from the Phase 1 clinical trial of GNSC-001 for the treatment of osteoarthritis demonstrated that it was safe and well tolerated.